AACR 2021: Humanized IL17A/IL17F mouse model provides a preclinical tool for the evaluation of therapeutic drugs targeting to IL-17 pathway

AACR 2021: Humanized IL17A/IL17F mouse model provides a preclinical tool for the evaluation of therapeutic drugs targeting to IL-17 pathway

• Expression of the proinflammatory cytokine interleukin 17 (IL-17) by activated CD4+ T cells has been associated with autoimmune disease pathogenesis.
• Biocytogen generated a double humanized B-hIL17A/hIL17F mouse model by replacing the sequences encoding the mouse Il17a and Il17f extracellular domains with the corresponding human sequences. 
• Psoriasis was induced in B-hIL17A/hIL17F mice to evaluate the in vivo efficacy of anti-human IL17A and IL17F antibodies. 
• Erythema and scaling score of the skin was significantly reduced in B-hIL17A/hIL17F mice treated with anti-human IL17A and IL17F antibodies.
• B-hIL17A/hIL17F mice are a promising model for in vivo efficacy evaluation of IL17 related drug candidates for the treatment of autoimmune diseases.